RIVIVE FDA approval date
The FDA approved RIVIVE on 28 Jul 2023.
- FDA approval date
- 28 Jul 2023
- Source
- FDA record
Drug identity has not yet been verified against registry records
Also recorded as NALOXONE HYDROCHLORIDE
Included trials
No linked trials for this drug yet. Browse all trials
PDUFA dates and FDA decisions
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-07-28Day | RIVIVE | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA217722", "applicant_as_listed_by_fda": "HARM REDUCTION THERP", "brand_names": ["RIVIVE"], "active_ingredients": ["NALOXONE HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230728", "matched_on": "drug record created from this FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |